Sectors & IndustriesHealthcareMedical Instruments & Supplies

Best Medical Stocks to Buy Now (2025)

Top medical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best medical stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best medical stocks to buy right now are:

Pro Dex (NASDAQ:PDEX) is the #1 top medical stock out of 54 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Pro Dex (NASDAQ:PDEX) is: Value: C, Growth: B, Momentum: B, Sentiment: A, Safety: C, Financials: C, and AI: D.

Pro Dex (NASDAQ:PDEX) has a Due Diligence Score of 50, which is 21 points higher than the medical industry average of 29.

PDEX passed 17 out of 33 due diligence checks and has strong fundamentals. Pro Dex has seen its stock return 174.99% over the past year, overperforming other medical stocks by 185 percentage points.

Pro Dex has an average 1 year price target of $52.00, an upside of 6.3% from Pro Dex's current stock price of $48.92.

Pro Dex stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Pro Dex, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Infusystem Holdings (NYSEMKT:INFU) is the #2 top medical stock out of 54 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: B, Momentum: C, Sentiment: D, Safety: C, Financials: A, and AI: B.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 29, which is equal to the medical industry average of 29.

INFU passed 9 out of 33 due diligence checks and has average fundamentals. Infusystem Holdings has seen its stock lose -35.15% over the past year, underperforming other medical stocks by -25 percentage points.

Resmed (NYSE:RMD) is the #3 top medical stock out of 54 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Resmed (NYSE:RMD) is: Value: C, Growth: C, Momentum: C, Sentiment: C, Safety: C, Financials: A, and AI: B.

Resmed (NYSE:RMD) has a Due Diligence Score of 56, which is 27 points higher than the medical industry average of 29.

RMD passed 21 out of 38 due diligence checks and has strong fundamentals. Resmed has seen its stock return 13.41% over the past year, overperforming other medical stocks by 24 percentage points.

Resmed has an average 1 year price target of $264.43, an upside of 20.36% from Resmed's current stock price of $219.70.

Resmed stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Resmed, 42.86% have issued a Strong Buy rating, 14.29% have issued a Buy, 42.86% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 8 medical stocks that have issued dividends in the past year, the 3 medical stocks with the highest dividend yields are:

Embecta (NASDAQ:EMBC) has an annual dividend yield of 2.34%, which is 1 percentage points higher than the medical industry average of 1.49%.

Embecta's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Utah Medical Products (NASDAQ:UTMD) has an annual dividend yield of 2.13%, which is 1 percentage points higher than the medical industry average of 1.49%. Utah Medical Products's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Utah Medical Products's dividend has shown consistent growth over the last 10 years.

Utah Medical Products's dividend payout ratio of 28.1% indicates that its dividend yield is sustainable for the long-term.

Baxter International (NYSE:BAX) has an annual dividend yield of 1.9%, which is the same as the medical industry average of 1.49%. Baxter International's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Baxter International's dividend has not shown consistent growth over the last 10 years.

Baxter International's dividend payout ratio of -81.9% indicates that its dividend yield might not be sustainable for the long-term.

Medical stocks were down -0.19% in the last day, and up 0.28% over the last week.

We couldn't find a catalyst for why medical stocks are down.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued medical stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued medical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 39 points higher than the medical industry average of 18. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -1.31% in the past year. It has overperformed other stocks in the medical industry by 9 percentage points.

Teleflex (NYSE:TFX) is the second most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Teleflex has a valuation score of 29, which is 11 points higher than the medical industry average of 18. It passed 2 out of 7 valuation due diligence checks.

Teleflex's stock has dropped -36.91% in the past year. It has underperformed other stocks in the medical industry by -27 percentage points.

Hologic (NASDAQ:HOLX) is the third most undervalued medical stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Hologic has a valuation score of 71, which is 53 points higher than the medical industry average of 18. It passed 5 out of 7 valuation due diligence checks.

Hologic's stock has dropped -18.6% in the past year. It has underperformed other stocks in the medical industry by -8 percentage points.

54.05% of medical stocks rated by analysts are a strong buy right now. On average, analysts expect medical stocks to rise by 31.25% over the next year.

0% of medical stocks have a Zen Rating of A (Strong Buy), 23.81% of medical stocks are rated B (Buy), 57.14% are rated C (Hold), 11.9% are rated D (Sell), and 7.14% are rated F (Strong Sell).